Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic area
Background: Carbapenem-resistant Enterobacterales (CRE) are included in the critical priority pathogens by WHO. OXA-48 is the predominating carbapenemase in Türkiye, in where carbapenem resistance rates are high, particularly in Klebsiella pneumoniae isolates. Ceftazidime-Avibactam (CAZ-AVI) has bee...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716524002807 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846106930959876096 |
|---|---|
| author | Şevval Arduç Tok Ayşe Barış Leyla Genç Hanife Tutan Elif Aktaş |
| author_facet | Şevval Arduç Tok Ayşe Barış Leyla Genç Hanife Tutan Elif Aktaş |
| author_sort | Şevval Arduç Tok |
| collection | DOAJ |
| description | Background: Carbapenem-resistant Enterobacterales (CRE) are included in the critical priority pathogens by WHO. OXA-48 is the predominating carbapenemase in Türkiye, in where carbapenem resistance rates are high, particularly in Klebsiella pneumoniae isolates. Ceftazidime-Avibactam (CAZ-AVI) has been used successfully in CRE infections in recent years, but resistance is reported to be on the rise. Aim: To evaluate the susceptibility to CAZ-AVI in CRE isolates and association of CAZ-AVI resistance and carbapenemase genes. Methods: CRE isolates from various clinical samples between January 2022 and June 2024 were included in the study. The isolates were identified by VITEK-MS(bioMerieux, France) system. Antibiotic susceptibilities were determined by VITEK COMPACT 2(BioMerieux, France) and CAZ-AVI susceptibility was evaluated by disk diffusion method(Oxoid, Thermo Fisher Scientific, Canada) according to EUCAST criteria. Carbapenemase genes were investigated in 324 representative isolates using Biospeedy Carbapenem-Resistance qPCR kit(Bioeksen, Türkiye). Results: The study included 429 CRE isolates. The distribution of CAZ-AVI susceptibility of CRE isolates according to sample type and clinics is shown in Table 1 and Table 2. CAZ-AVI susceptibility of isolates according to carbapenemase genes is presented in Table 3. In total, CAZ-AVI susceptibility of CRE isolates was 76%, while it was 99.5% in non-metallo-beta-lactamase (MBL) producers and 100% in only OXA-48-like producers. Conclusıons: Despite the increasing resistance in CRE isolates, CAZ-AVI is still a good option for treatment. CAZ-AVI was found to be highly effective particularly in isolates with non-MBL carbapenemase genes. Early detection of carbapenemase type is important in predicting CAZ-AVI susceptibility. |
| format | Article |
| id | doaj-art-7b7d351ae5d34fd39f577bb251646b83 |
| institution | Kabale University |
| issn | 2213-7165 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj-art-7b7d351ae5d34fd39f577bb251646b832024-12-27T04:08:29ZengElsevierJournal of Global Antimicrobial Resistance2213-71652024-12-013933Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic areaŞevval Arduç Tok0Ayşe Barış1Leyla Genç2Hanife Tutan3Elif Aktaş4University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Department of Medical MicrobiologyUniversity of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Department of Medical MicrobiologyUniversity of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Department of Medical MicrobiologyUniversity of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Department of Medical MicrobiologyUniversity of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Department of Medical MicrobiologyBackground: Carbapenem-resistant Enterobacterales (CRE) are included in the critical priority pathogens by WHO. OXA-48 is the predominating carbapenemase in Türkiye, in where carbapenem resistance rates are high, particularly in Klebsiella pneumoniae isolates. Ceftazidime-Avibactam (CAZ-AVI) has been used successfully in CRE infections in recent years, but resistance is reported to be on the rise. Aim: To evaluate the susceptibility to CAZ-AVI in CRE isolates and association of CAZ-AVI resistance and carbapenemase genes. Methods: CRE isolates from various clinical samples between January 2022 and June 2024 were included in the study. The isolates were identified by VITEK-MS(bioMerieux, France) system. Antibiotic susceptibilities were determined by VITEK COMPACT 2(BioMerieux, France) and CAZ-AVI susceptibility was evaluated by disk diffusion method(Oxoid, Thermo Fisher Scientific, Canada) according to EUCAST criteria. Carbapenemase genes were investigated in 324 representative isolates using Biospeedy Carbapenem-Resistance qPCR kit(Bioeksen, Türkiye). Results: The study included 429 CRE isolates. The distribution of CAZ-AVI susceptibility of CRE isolates according to sample type and clinics is shown in Table 1 and Table 2. CAZ-AVI susceptibility of isolates according to carbapenemase genes is presented in Table 3. In total, CAZ-AVI susceptibility of CRE isolates was 76%, while it was 99.5% in non-metallo-beta-lactamase (MBL) producers and 100% in only OXA-48-like producers. Conclusıons: Despite the increasing resistance in CRE isolates, CAZ-AVI is still a good option for treatment. CAZ-AVI was found to be highly effective particularly in isolates with non-MBL carbapenemase genes. Early detection of carbapenemase type is important in predicting CAZ-AVI susceptibility.http://www.sciencedirect.com/science/article/pii/S2213716524002807ceftazidime-avibactamcarbapenem resistance enterobacteralescarbapenemase genesoxa-48 |
| spellingShingle | Şevval Arduç Tok Ayşe Barış Leyla Genç Hanife Tutan Elif Aktaş Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic area Journal of Global Antimicrobial Resistance ceftazidime-avibactam carbapenem resistance enterobacterales carbapenemase genes oxa-48 |
| title | Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic area |
| title_full | Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic area |
| title_fullStr | Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic area |
| title_full_unstemmed | Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic area |
| title_short | Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic area |
| title_sort | ceftazidim avibactam susceptibility of carbapenemase producing enterobacterales in an oxa 48 endemic area |
| topic | ceftazidime-avibactam carbapenem resistance enterobacterales carbapenemase genes oxa-48 |
| url | http://www.sciencedirect.com/science/article/pii/S2213716524002807 |
| work_keys_str_mv | AT sevvalarductok ceftazidimavibactamsusceptibilityofcarbapenemaseproducingenterobacteralesinanoxa48endemicarea AT aysebarıs ceftazidimavibactamsusceptibilityofcarbapenemaseproducingenterobacteralesinanoxa48endemicarea AT leylagenc ceftazidimavibactamsusceptibilityofcarbapenemaseproducingenterobacteralesinanoxa48endemicarea AT hanifetutan ceftazidimavibactamsusceptibilityofcarbapenemaseproducingenterobacteralesinanoxa48endemicarea AT elifaktas ceftazidimavibactamsusceptibilityofcarbapenemaseproducingenterobacteralesinanoxa48endemicarea |